Diamyd Medical - curing diabetes.

The Company´s mission is to contribute in the global effort to find this cure and to eliminate complications from the disease. Accordingly, the Company currently develops therapeutics from two independent platform technologies. One of these platforms relies on the GAD65 molecule and the other on a viral delivery system of proteins to nervous tissue (Nerve Targeted Drug Delivery System, NTDDS). Therapeutics for conditions other than diabetes are also being developed using these platforms.

Diamyd Medical´s furthest developed products are the vaccine Diamyd® for type 1-diabetes (Phase III) and the vaccine Diamyd® for LADA (Phase II). GAD65 is a major autoantigen in autoimmune diabetes and both of the Diamyd® vaccines are intended to induce immunotolerization.

Diamyd is a Swedish public company listed on the OMX Nasdaq Nordic list. The company has headquarters in Stockholm, Sweden and offices in Pittsburgh, Pennsylvania.

www.diamyd.com

Top^